Skip to main content
Log in

Wirkungsmechanismus von Canagliflozin

Mechanism of action for canagliflozin

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. Die Spitzenplasmakonzentration beim Menschen nach Einnahme der zugelassenen Maximaldosis von 300 mg Canagliflozin liegt bei ~10 µmol/l.

Literatur

  1. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, O’Neill HM, Ford RJ, Palanivel R, O’Brien M, Hardie DG, Macaulay SL, Schertzer JD, Dyck JR, van Denderen BJ, Kemp BE, Steinberg GR (2013) Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 19(12):1649–1654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G, Qiu R (2016) Initial combination therapie with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care 39:353–362

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Kahl.

Ethics declarations

Interessenkonflikt

S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kahl, S. Wirkungsmechanismus von Canagliflozin. Diabetologe 12, 434–436 (2016). https://doi.org/10.1007/s11428-016-0131-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-016-0131-4

Navigation